Citron Research Out Negative on J2 Global (JCOM)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P, Dow edge higher on Mideast deal hopes; SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil falls to near two-month lows as Trump calls off threatened strikes on Iran
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
Early Valeant/Walgreens Boots Prescription Trends Continuing to Look Positive - Guggenheim (VRX) (WBA)
March 11, 2016 9:37 AM ESTGuggenheim affirms Valeant Pharma (NYSE: VRX) with a Buy rating and $145 price target following recent dermatology prescription performance checks.
Analyst Louise Chen noted the following on Friday:
VRX dermatology Rxs reached ~80% of their levels prior to any disruption from Philidor (October '15) levels up from ~75% last week. TRx's for derm... MoreJ2 Global (JCOM) Comments on Citron Report; Calls 'Factually Incorrect'
March 11, 2016 6:06 AM ESTj2 Global, Inc. (Nasdaq: JCOM). j2 is aware of a report issued yesterday that we believe is both factually incorrect and wrongly... More
UPDATE: Is J2 Global (JCOM) Short a Blast from the Past?
March 10, 2016 2:06 PM EST(Updated - March 10, 2016 3:04 PM EST)
Some traders are suggesting Citron Research was recommending a short on J2 Global (NASDAQ: JCOM) 10 years ago when it was Stocklemon. It is unclear if this is the case. Shares are hitting the lows of the session down 20%... More
